The Catalyst

Most Recent Posts


This is a "they missed the real story" story. Yesterday, Phama Times ran a story on the effort of a small group of Congressmen to keep biosimilars out of any Trans-Pacific trade deal. The story was factual so far as it goes and, certainly, it did note PhRMA's long-standing position on biosimilars data protection:

08.16.11 | By Kate Connors

Until yesterday, biopharmaceutical research companies were allowed to disable comments from users on certain Facebook pages. This helped companies ensure that those pages were sources of accurate information, though it meant they were removing some ability to engage the public in a dialogue.

08.15.11 | By Kate Connors

As part of our current emphasis on arthritis awareness - based on our recent release of our Medicines in Development report on musculoskeletal disorders - we sat down recently to speak with Kelly Rouba, who has lived with arthritis for most of her life.

08.10.11 | By Kate Connors

You may have noticed that we've been writing a lot about Medicare Part D lately, but with good reason. From lowered nondrug costs to decreased premiums, there are so many successes of the Medicare prescription drug benefit to celebrate these days.


Austin Frakt over at the Incidental Economist weighs in on the recent JAMA study on the value of the Medicare Part D program. The JAMA study found that Part D saves Medicare about $1,200 per year in hospital, nursing home and other costs for each senior who previously lacked comprehensive prescription drug coverage.

A great movie script is about allowing the audience to suspend their disbelief. Science fiction movies, in particular, require great imagination and an ability to credibly postulate alternative realities. All of which brings me to the new movie that premiered this weekend: The Rise of the Battle for the Planet of the Apes.
The list of inefficient and costly government programs in America today is a long one. But at least one program is performing far better than expected and is costing less than anyone ever anticipated - it's Medicare Part D. Part D's success is remarkable. It's a federal program that seniors like, it's saving them money on their medicines and it's helping them stay healthy. That means reducing their need for some of the most costly health care services like hospitalizations and nursing homes.
08.04.11 | By Kate Connors
Recently Merck researcher Dr. Rupert Vessey sat down with PhRMA to talk about arthritis, especially rheumatoid arthritis, and the importance of treatment in this field.

Last week we were talking a lot about the JAMA study showing how proper use of prescription medicines by Part D beneficiaries is helping to reduce overall Medicare non-drug medical expenditures.

08.01.11 | By Kate Connors
Monday's Wall Street Journal features an op-ed (subscription) by Margaret Hamburg, the commissioner of the Food and Drug Administration, who discusses the difficult balance that the agency strives to achieve between protecting the public health through regulation and promoting innovation and access.

Yesterday, we were talking about a new study in the Journal of the American Medical Association (JAMA) that found that proper use of prescription medicines by Part D beneficiaries is helping to reduce non-drug medical expenditures in Medicare overall. The core of the JAMA study:

07.27.11 | By Kate Connors

Once again, we're looking at the value of access to prescription medicines today, fueled by a study in today's Journal of the American Medical Association (subscription required).


A recent AP poll found that baby boomers' (born between 1946 and 1964) health concerns are focused mostly on possible cancers and memory loss. Obviously, these are important concerns for everyone as they age.

07.26.11 | By Kate Connors

A recent article lauding a so-called "looming wave of new generic pills," like many similar articles, fails to paint the bigger picture: that generics, while an important part of the healthcare system, ultimately play a limited role for patients.

07.22.11 | By Kate Connors
This week, a respected Maryland-based company announced that it is instituting a voluntary layoff program to thousands of its employees, representing the potential for significant job loss throughout the state and the region. It's a company that is dedicated to innovating, to building on previous successes to create novel products that surpass what came before. It is a company that invests heavily in its products and a company that is highly regulated.